Gastroenterology
Volume 139, Issue 1 , Pages 7-13.e3 , July 2010

Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease

  • Evan S. Dellon
    • ,
  • Nicholas J. Shaheen

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Nicholas J. Shaheen, MD, MPH, CB#7080, Bioinformatics Building, 130 Mason Farm Road, UNC-CH, Chapel Hill, NC 27599-7080. fax: (919) 843-2508

References 

  1. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575–583
  2. Kahrilas PJ, Falk GW, Johnson DA, et al. The Esomeprazole Study Investigators Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14:1249–1258
  3. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28–34
  4. AGA. GERD patient study: Patients and their medications. http://www.gastro.org/user-assets/documents/13_Media/GERD_Survey_Final_Report_2.pdf,2008Accessed March 24, 2010
  5. Dean BB, Gano AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664

 Conflicts of interest The authors disclose the following: Nicholas J. Shaheen receives research funding from AstraZeneca, BARRX Medical, CSA Medical, Oncoscope Procter & Gamble, and Takeda, and is a consultant for AstraZeneca, CSA Medical, Oncoscope, and Takeda. Evan S. Dellon receives investigator-initiated research funding from AstraZeneca.

PII: S0016-5085(10)00744-4

doi: 10.1053/j.gastro.2010.05.016

Gastroenterology
Volume 139, Issue 1 , Pages 7-13.e3 , July 2010

Article Tools

* Image Usage & Resolution